NCT06973863View on ClinicalTrials.gov

A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions

Advanced Solid TumorSolid TumorsMTAP-deleted Solid TumorsMTAP Deletion

Interventions

DRUG

PEP08

PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.

Trial Locations (1)

2145

Westmead Hospital, Wentworthville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

PharmaEngine

INDUSTRY